Novavax, Inc. (NVAX)

About Novavax, Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

As of November 3, 2026, Novavax, Inc. (NVAX) stock climbed to $9.73, up 2.15% (+$0.21) versus the previous close. On the day, shares have traded between $9.45 and $9.95. That puts NVAX around the middle of its 52-week range of $6.20 to $13.39. Novavax, Inc. operates in the biological products, (no diagnostic substances) space and carries a market capitalization of roughly $1.66 billion, with about 1.93 million shares changing hands.

Latest NVAX news

• Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropeYahoo Finance· Oct 29, 9:15 AM ET
• Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseYahoo Finance· Oct 29, 9:00 AM ET
• Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026Yahoo Finance· Oct 29, 8:00 AM ETET
• Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher247wallst.com· Oct 28, 12:04 PM ET
• Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to KnowYahoo Finance· Oct 26, 4:45 PM ET
• What Novavax Doubters OverlookedYahoo Finance· Oct 24, 3:09 AM ET
• 3 small-cap stocks walking a fine lineYahoo Finance· Oct 23, 4:24 PM ET
• Is Novavax (NVAX) Fully Priced Relative To Its Sales Base?Yahoo Finance· Oct 23, 3:08 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want NVAX headlines, alerts and AI research in one place? Create a free account →

• @GhostRazer Yeah that partner read tracks imo on $NVAX. Thursday is a checkpoint for me, not the promised land moment. If Sanofi or Pfizer show real progress, the rest of the partner list gets a lot more interesting fast.

  @BiotechSwings· Nov 3, 2:04 PM ET

• $NVAX Prevnar35 makes sense. Look at the adjuvants and the adjuvant free versions has twice the amount of antigen. Matrix M = antigen sparing, type of immune response th1 + th2 etc

  @UndSchwung· Nov 3, 2:00 PM ET

• Thanks for keeping me green in this red market. Made $5.2K profits :) Make sure you drop a Follow to @PremiumCollection below. He's been calling some insane runners 💯🥂 Will be loading more $NVAX $IREN $NBIS for swings

  @RagnirLothbrok· Nov 3, 1:58 PM ET· Bullish

• $NVAX I didn't see ERs or listen to the ECs for Pfiser or Sanofi but based on comments from other posters here it seems like they didn't shower us with love. Seems that Sanofi for sure and likely Pfiser too are the farthest along in researching potential projects with …

  @GhostRazer· Nov 3, 1:57 PM ET

• $NVAX 5 years of "Happy Talk" Jacobs. He's gotten fabulously wealthy and shareholders have gotten poor. And he keeps getting rewarded for poor execution and mismanagement.

  @BensonFuller· Nov 3, 1:10 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →